We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
In what appears to be a response to manufacturer complaints regarding “black box” Inflation Reduction Act (IRA) drug price negotiations, the ...
Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.
Monica Martin de Bustamante, senior partner and head of advisory at Trinity Life Sciences, spoke with Pharmaceutical ...
The root of the U.S.’s high prescription drug prices lies in its unique system, which allows pharmaceutical manufacturers to ...
Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...
The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.
(Under Azar, Eli Lilly tripled the price of its top-selling insulin drug.) But President Joe Biden's Inflation ... as the ...